Pancreastatin is a 49 amino acid peptide produced by degradation of Chromo-granin A.  It inhibits Chromogranin A and Parathyroid Hormone release.  Pancreastatin also inhibits release of Somatostatin upon glucose stimulation.  It may also control carbohydrate metabolism and hyperglycemia.  Although there are no compounds with significant structural homology with Pancreastatin, there are minor similarities to Gastrin and Anti-Diuretic Hormone.  Pancreastatin reduces the the early phase of Glucose induced Insulin release.  Suppression of Insulin release upon Glucose stimulation is a characteristic feature of Type II Diabetes.  Pancreastatin could play an important therapeutic role in the treatment of diabetes.  Pancreastatin also inhibits release of Somatostatin.  It may also control carbohydrate metabolism and hyperglycemia.

Patient should not be on any medications that may influence Insulin levels, if possible, for at least 48 hours prior to collection.

Z-collection plasma vial/tube

Immediately following collection, mix sample thoroughly by gently inverting 8 - 10 times to prevent clotting

1. Spin within two (2) hours of sample collection
2. Transfer plasma to a Amber screw-cap polypropylene frozen transport tube/vial - 4mL (LabCorp), labelled as Z tube plasma
3. Freeze

Amber screw-cap polypropylene frozen transport tube/vial - 4mL (LabCorp)

Frozen (strict) - 14 days

Direct radioimmunoassay

Up to 135 pg/mL